News Information

The research and development achievements of the anti-liver cancer traditional Chinese medicine - Sanjie Pian have been included in the "National Science and Technology Achievements Database."


Release time:

2022-04-19

In 2021, the anti-liver cancer traditional Chinese medicine - Sanjie Pian passed the expert review by the Ministry of Science and Technology, achieving a level of technological advancement that is considered leading in the country. The research and development results have been included in the National Science and Technology Achievements Database (No. 6012021Y0389). It was publicly announced on the National Science and Technology Achievements Registration Work Platform (Guokewang) in March 2022.

In 2021, the anti-liver cancer traditional Chinese medicine - Sanjie Pian passed the expert review of the Ministry of Science and Technology, achieving a level of domestic advanced technology. The research and development results were included in the National Science and Technology Achievement Database (No. 6012021Y0389) and were publicly announced in March 2022 on the National Science and Technology Achievement Registration Work Platform (Guokewang).

 

 

The anti-liver cancer traditional Chinese medicine - Sanjie Pian, with the National Medicine Approval Number, is a patented product exclusively developed and produced by Zhuhai Miditech Biopharmaceutical Co., Ltd. The emergence of Sanjie Pian has brought hope to patients with liver cancer and liver cirrhosis. Sanjie Pian effectively prevents the recurrence and metastasis of liver cancer, while also reducing alpha-fetoprotein (which can prevent and stop the transformation of hepatitis B to liver cancer) and alleviating pain. It has an inhibitory effect on the growth of primary liver cancer and, when combined with interventional chemotherapy, can significantly improve clinical efficacy. The combination of traditional Chinese medicine Sanjie Pian + Beiqinglong Yi decoction + interventional chemotherapy for the treatment of liver cancer and liver cirrhosis has achieved good clinical results. We are currently applying for a national project on the integration of traditional Chinese and Western medicine for this topic. The combination of Sanjie Pian + Beiqinglong Yi + chemotherapy has also achieved good clinical results for pancreatic cancer. Unexpected effects have been observed in patients with pancreatic cancer metastasized to liver cancer (secondary liver cancer). The combination of Sanjie Pian + PD1 for the treatment of liver cancer is also in the process of applying for a national project on the integration of traditional Chinese and Western medicine. Professor Zheng Yongqi from Yale University in the United States used a classic traditional Chinese medicine formula + PD1 combination therapy to make all tumors in mice disappear, setting a precedent for this project application.

 

 

China is a major country for hepatitis B, with the incidence and mortality rates of liver cancer ranking first in the world. There are 450 million chronic liver disease patients in China. To achieve the goal of a healthy China by 2030, we must address the rehabilitation of these 450 million chronic liver disease patients. Sanjie Pian is precisely the best choice to realize the goal of a "healthy China, cancer-free China."

Related Information

Anti-liver cancer and liver cirrhosis traditional Chinese medicine - Sanjie Pian, safeguarding 447 million chronic liver disease patients.

Traditional Chinese Medicine for Liver Cancer and Liver Cirrhosis - Sanjie Pian, safeguarding 447 million chronic liver disease patients.

See more →

The research and development achievements of the anti-liver cancer traditional Chinese medicine - Sanjie Pian have been included in the "National Science and Technology Achievements Database."

In 2021, the anti-liver cancer traditional Chinese medicine - Sanjie Pian passed the expert review by the Ministry of Science and Technology, achieving a level of technological advancement that is considered leading in the country. The research and development results have been included in the National Science and Technology Achievements Database (No. 6012021Y0389). It was publicly announced on the National Science and Technology Achievements Registration Work Platform (Guokewang) in March 2022.

See more →